KR101824512B1 - 과립구-대식세포 콜로니 자극 인자에 대한 항체 - Google Patents

과립구-대식세포 콜로니 자극 인자에 대한 항체 Download PDF

Info

Publication number
KR101824512B1
KR101824512B1 KR1020107026423A KR20107026423A KR101824512B1 KR 101824512 B1 KR101824512 B1 KR 101824512B1 KR 1020107026423 A KR1020107026423 A KR 1020107026423A KR 20107026423 A KR20107026423 A KR 20107026423A KR 101824512 B1 KR101824512 B1 KR 101824512B1
Authority
KR
South Korea
Prior art keywords
antibody
sequence
seq
region
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020107026423A
Other languages
English (en)
Korean (ko)
Other versions
KR20110011638A (ko
Inventor
크리스토퍼 알. 베빙턴
케네스 루어센
제프리 티. 야란톤
Original Assignee
휴머니건, 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 휴머니건, 아이엔씨. filed Critical 휴머니건, 아이엔씨.
Publication of KR20110011638A publication Critical patent/KR20110011638A/ko
Application granted granted Critical
Publication of KR101824512B1 publication Critical patent/KR101824512B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
KR1020107026423A 2008-04-28 2009-04-28 과립구-대식세포 콜로니 자극 인자에 대한 항체 Active KR101824512B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4852208P 2008-04-28 2008-04-28
US61/048,522 2008-04-28
PCT/US2009/041981 WO2009134805A2 (en) 2008-04-28 2009-04-28 Antibodies to granulocyte-macrophage colony-stimulating factor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177023943A Division KR101852915B1 (ko) 2008-04-28 2009-04-28 과립구-대식세포 콜로니 자극 인자에 대한 항체

Publications (2)

Publication Number Publication Date
KR20110011638A KR20110011638A (ko) 2011-02-08
KR101824512B1 true KR101824512B1 (ko) 2018-02-02

Family

ID=41255734

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020107026423A Active KR101824512B1 (ko) 2008-04-28 2009-04-28 과립구-대식세포 콜로니 자극 인자에 대한 항체
KR1020177023943A Active KR101852915B1 (ko) 2008-04-28 2009-04-28 과립구-대식세포 콜로니 자극 인자에 대한 항체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177023943A Active KR101852915B1 (ko) 2008-04-28 2009-04-28 과립구-대식세포 콜로니 자극 인자에 대한 항체

Country Status (17)

Country Link
US (3) US8168183B2 (https=)
EP (2) EP2280732B1 (https=)
JP (1) JP5688363B2 (https=)
KR (2) KR101824512B1 (https=)
CN (1) CN102037016B (https=)
AU (1) AU2009243184B2 (https=)
BR (1) BRPI0911902A2 (https=)
CA (1) CA2722137C (https=)
CO (1) CO6311004A2 (https=)
DK (1) DK2280732T3 (https=)
EA (1) EA201001691A1 (https=)
ES (1) ES2704835T3 (https=)
IL (1) IL208980A (https=)
MX (1) MX2010011761A (https=)
NZ (1) NZ588850A (https=)
WO (1) WO2009134805A2 (https=)
ZA (1) ZA201008028B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE536374T1 (de) 2006-09-01 2011-12-15 Therapeutic Human Polyclonals Inc Erhöhte expression von humanem oder humanisiertem immunglobulin bei nicht-humanen transgenen tieren
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
NZ588850A (en) 2008-04-28 2012-12-21 Kalobios Pharmaceuticals Inc Antibodies to granulocyte-macrophage colony-stimulating factor
EP3056217B1 (en) * 2008-12-22 2021-06-30 The University of Melbourne Osteoarthritis treatment
RU2630969C2 (ru) 2008-12-22 2017-09-15 Де Юниверсити Оф Мельбурн Лечение боли
WO2012012571A1 (en) 2010-07-21 2012-01-26 Hans Zassenhaus Biolayer interferometry measurement of biological targets
EP2729498A1 (en) 2011-07-06 2014-05-14 MorphoSys AG Therapeutic combinations of anti -cd20 and anti - gm - csf antibodies and uses thereof
US9400600B2 (en) * 2011-12-16 2016-07-26 Samsung Electronics Co., Ltd. Method, apparatus, and graphical user interface for providing visual effects on a touchscreen display
WO2013090989A1 (en) 2011-12-22 2013-06-27 Csl Limited Method of treating inflammatory bowel disease
EP2914289B1 (en) 2012-10-31 2019-05-22 Takeda GmbH Lyophilized formulation comprising gm-csf neutralizing compound
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
US10745475B2 (en) * 2013-08-30 2020-08-18 Takeda Gmbh Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
EP3139960B1 (en) 2014-05-07 2024-01-17 Takeda Pharmaceutical Company Limited Liquid formulation comprising gm-csf neutralizing compound
CN113862300A (zh) * 2015-10-29 2021-12-31 豪夫迈·罗氏有限公司 具有共同轻链的转基因兔
EP3691663A4 (en) * 2017-10-02 2021-08-18 Humanigen, Inc. METHODS OF TREATMENT OF TOXICITY ASSOCIATED WITH IMMUNOTHERAPIES USING A GM-CSF ANTAGONIST
US11130805B2 (en) 2017-10-02 2021-09-28 Humanigen, Inc. Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
SG11202102317PA (en) * 2018-09-10 2021-04-29 Humanigen Inc Methods of treating immunotherapy-related toxicity using a gm-csf antagonist
SG11202103589XA (en) 2018-10-31 2021-05-28 Humanigen Inc Materials and methods for treating cancer
TW202134278A (zh) 2019-11-08 2021-09-16 美商胡曼尼根公司 用於治療腫瘤之ｅｐｈａ３導向ｃａｒ－ｔ細胞
CN118561999B (zh) * 2024-06-26 2025-03-14 武汉爱博泰克生物科技有限公司 抗人粒细胞-巨噬细胞集落刺激因子抗体、抗体对及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003068920A2 (en) * 2002-02-13 2003-08-21 Ludwig Institute For Cancer Research Humanized gm-csf antibodies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ES2263984T3 (es) * 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
CA2513113A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
JP4782700B2 (ja) 2004-01-20 2011-09-28 カロバイオス ファーマシューティカルズ インコーポレイティッド 最低限必須な結合決定基を用いた抗体特異性の移入
US20060134098A1 (en) * 2004-11-16 2006-06-22 Kalobios, Inc. Immunoglobulin variable region cassette exchange
US7381802B2 (en) * 2005-04-15 2008-06-03 Universidad Nacional Autónoma De México (UNAM) Human antibodies that specifically recognize the toxin Cn2 from Centruroides noxius scorpion venom
EP2468774A3 (en) * 2005-04-18 2013-01-02 Amgen Research (Munich) GmbH Antibody neutralizers of human granulocyte macrophage colony stimulating factor
EP3620171B1 (en) * 2005-05-18 2022-04-20 MorphoSys AG Anti-gm-csf antibodies and uses therefor
US8211648B2 (en) 2005-07-22 2012-07-03 Kalobios Pharmaceuticals, Inc. Secretion of antibodies without signal peptides from bacteria
KR20080068004A (ko) * 2005-08-15 2008-07-22 아라나 테라퓨틱스 리미티드 뉴 월드 영장류 구조형성영역을 가진 조작 항체
CA2641169C (en) * 2006-02-08 2017-05-02 Morphotek, Inc. Antigenic gm-csf peptides and antibodies to gm-csf
US8398972B2 (en) * 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
US20080206241A1 (en) 2006-11-21 2008-08-28 Kalobios Pharmaceuticals Inc. Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF Antagonist
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
US8075885B2 (en) * 2008-04-07 2011-12-13 Kalobios Pharmaceuticals, Inc. Methods of treating heart failure using an anti-GM-CSF antibody
NZ588850A (en) 2008-04-28 2012-12-21 Kalobios Pharmaceuticals Inc Antibodies to granulocyte-macrophage colony-stimulating factor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003068920A2 (en) * 2002-02-13 2003-08-21 Ludwig Institute For Cancer Research Humanized gm-csf antibodies

Also Published As

Publication number Publication date
AU2009243184B2 (en) 2015-06-04
US9017674B2 (en) 2015-04-28
US8168183B2 (en) 2012-05-01
WO2009134805A3 (en) 2010-06-03
JP2011518886A (ja) 2011-06-30
DK2280732T3 (en) 2019-01-28
EP3449941A1 (en) 2019-03-06
CN102037016B (zh) 2015-06-03
CA2722137C (en) 2019-03-19
KR20110011638A (ko) 2011-02-08
WO2009134805A2 (en) 2009-11-05
BRPI0911902A2 (pt) 2015-10-13
US20090274706A1 (en) 2009-11-05
MX2010011761A (es) 2010-11-30
IL208980A0 (en) 2011-01-31
ZA201008028B (en) 2012-04-25
EP2280732B1 (en) 2018-10-17
US20120213776A1 (en) 2012-08-23
ES2704835T3 (es) 2019-03-20
EA201001691A1 (ru) 2011-10-31
US20150344565A1 (en) 2015-12-03
CO6311004A2 (es) 2011-08-22
AU2009243184A1 (en) 2009-11-05
CN102037016A (zh) 2011-04-27
EP2280732A2 (en) 2011-02-09
IL208980A (en) 2015-06-30
JP5688363B2 (ja) 2015-03-25
KR101852915B1 (ko) 2018-04-27
NZ588850A (en) 2012-12-21
EP2280732A4 (en) 2012-11-14
KR20170126458A (ko) 2017-11-17
CA2722137A1 (en) 2009-11-05

Similar Documents

Publication Publication Date Title
KR101824512B1 (ko) 과립구-대식세포 콜로니 자극 인자에 대한 항체
US11673962B2 (en) Method of increasing the efficacy of CAR-T immunotherapy using lenzilumab
EP2101780A2 (en) Methods of treating chronic inflammatory diseases using a gm-csf antagonist
CN113861294A (zh) 针对犬白介素-4受体α的抗体
CN108473568A (zh) 对TNF-α、IL-17A和IL-17F具有特异性的多特异性抗体分子
CN116133684B (zh) 抗人nr1抗体衍生物
WO2014028748A1 (en) Interleukin 2 antibodies and antibody complexes
JP2023109987A (ja) 抗ヒトｇｐｖｉ抗体を用いた血小板凝集の阻害
CN114539418A (zh) 双特异性抗体及其用途
CN120554509A (zh) 靶向CD3e/g的抗体或其抗原结合片段、其制备和应用
RU2825460C1 (ru) Антитела к TSLP человека и их применение
HK1148222B (en) Antibodies to granulocyte-macrophage colony-stimulating factor
HK1148222A (en) Antibodies to granulocyte-macrophage colony-stimulating factor
HK40003379A (en) Antibodies to granulocyte-macrophage colony stimulating factor
KR20240022546A (ko) 항il-36r 항체 및 그의 사용
HK40065460A (en) Bispecific antibody and use thereof
JP2024534824A (ja) 操作された抗ｈｅｒ２二重特異性タンパク質
CN117715932A (zh) 一种cdc平台抗体

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20101125

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140425

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20151229

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20161123

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20170525

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20170825

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20180126

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20180126

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20201023

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20201023

Start annual number: 4

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20240122

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20241031

Start annual number: 8

End annual number: 8